HUE054828T2 - Eljárások és készítmények a bél enteroendokrin rendszerének stimulálására a vele kapcsolatos betegségek és állapotok kezelésére - Google Patents
Eljárások és készítmények a bél enteroendokrin rendszerének stimulálására a vele kapcsolatos betegségek és állapotok kezeléséreInfo
- Publication number
- HUE054828T2 HUE054828T2 HUE15811714A HUE15811714A HUE054828T2 HU E054828 T2 HUE054828 T2 HU E054828T2 HU E15811714 A HUE15811714 A HU E15811714A HU E15811714 A HUE15811714 A HU E15811714A HU E054828 T2 HUE054828 T2 HU E054828T2
- Authority
- HU
- Hungary
- Prior art keywords
- stimulation
- compositions
- methods
- same
- treating diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462015657P | 2014-06-23 | 2014-06-23 | |
US14/329,627 US10040817B2 (en) | 2013-10-03 | 2014-07-11 | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE054828T2 true HUE054828T2 (hu) | 2021-10-28 |
Family
ID=54869043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE15811714A HUE054828T2 (hu) | 2014-06-23 | 2015-06-22 | Eljárások és készítmények a bél enteroendokrin rendszerének stimulálására a vele kapcsolatos betegségek és állapotok kezelésére |
Country Status (18)
Country | Link |
---|---|
US (10) | US10040817B2 (hu) |
EP (1) | EP3157531B1 (hu) |
JP (2) | JP6692300B2 (hu) |
CN (2) | CN106535902B (hu) |
BR (1) | BR112016029917A2 (hu) |
CA (1) | CA2951720C (hu) |
CY (1) | CY1124554T1 (hu) |
DK (1) | DK3157531T3 (hu) |
ES (1) | ES2878077T3 (hu) |
HR (1) | HRP20211005T1 (hu) |
HU (1) | HUE054828T2 (hu) |
LT (1) | LT3157531T (hu) |
MX (2) | MX2016017368A (hu) |
PL (1) | PL3157531T3 (hu) |
PT (1) | PT3157531T (hu) |
RS (1) | RS62064B1 (hu) |
SI (1) | SI3157531T1 (hu) |
WO (1) | WO2015200195A1 (hu) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
US20160058730A1 (en) * | 2014-08-29 | 2016-03-03 | Cadila Healthcare Limited | Pharmaceutical compositions of teriflunomide |
US20180344748A1 (en) * | 2017-05-31 | 2018-12-06 | Enterin Laboratories, Inc. | Methods and compositions for preventing or treating chronic inflammatory diseases |
WO2019050903A1 (en) * | 2017-09-08 | 2019-03-14 | Enterin Laboratories, Inc. | METHODS OF TREATING SLEEP DISORDERS, SLEEP DISTURBANCES AND ASSOCIATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS |
MA50536A (fr) | 2017-10-30 | 2020-09-09 | Enterin Inc | Nouvelles formes solides de squalamine et procédés pour les produire |
US20190298740A1 (en) * | 2018-03-27 | 2019-10-03 | Enterin, Inc. | Methods and compositions for treating hallucinations and conditions related to the same |
AU2019285065A1 (en) * | 2018-06-13 | 2021-01-07 | Enterin, Inc. | Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration |
US20210315907A1 (en) * | 2018-08-03 | 2021-10-14 | Enterin, Inc, | Compositions and methods for treating brain-gut disorders |
WO2020028810A1 (en) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Compositions and methods for treating brain-gut disorders |
EP3829537A4 (en) * | 2018-08-03 | 2022-09-21 | Enterin, Inc. | LOW DOSAGE INTRANASAL DOSAGE FORMS OF AMINOSTEROL AND METHODS OF USE THEREOF |
US11464789B2 (en) | 2018-08-03 | 2022-10-11 | Enterin, Inc. | Aminosterol compositions and methods of using the same for treating schizophrenia |
EP4007581A4 (en) * | 2019-08-02 | 2023-10-25 | Enterin, Inc. | DOSAGE PROTOCOLS AND REGIMES FOR AMINOSTEROL TREATMENT |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5192756A (en) | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
US5352682A (en) | 1993-03-08 | 1994-10-04 | Digestive Care Inc. | Compositions containing salts of bile acid-aminosalicylate conjugates |
WO1994020520A1 (en) | 1993-03-10 | 1994-09-15 | Magainin Pharmaceuticals Inc. | Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants |
US5840740A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds and a method of treating infection using the aminosterol compounds |
US5856535A (en) | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
AU3512595A (en) | 1994-09-13 | 1996-03-29 | Magainin Pharmaceuticals, Inc. | Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds |
US5834453A (en) | 1995-05-30 | 1998-11-10 | Lehigh University | Methods for the manufacture and use of antimicrobial sterol conjugates |
US5874597A (en) | 1995-06-07 | 1999-02-23 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
US5847172A (en) | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
US6143738A (en) | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
US5763430A (en) | 1995-06-07 | 1998-06-09 | Magainin Pharmaceuticals Inc. | Method of treating a viral infection by administering a steroid compound |
US5795885A (en) | 1995-06-07 | 1998-08-18 | Magainin Pharmaceuticals Inc. | Method of inhibiting profileration of cells by administering an aminosterol compound |
US5792635A (en) * | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
JP4104164B2 (ja) * | 1995-06-07 | 2008-06-18 | ジェネーラ コーポレーション | ナトリウム/プロトン交換体(nhe)の阻害剤として有用なアミノステロール化合物、同阻害剤を使用する薬学的方法および組成物、ならびに化合物のnhe阻害効果を評価する方法 |
US5994336A (en) | 1995-06-07 | 1999-11-30 | Magainin Pharmaceuticals Inc. | Method of inhibiting proliferation of cells by administering an aminosterol compound |
US5840936A (en) | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE) |
US5744453A (en) | 1996-01-05 | 1998-04-28 | Mintz; Clifford S. | Polyamine conjugates for treatment of infection |
US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
DE69722793T2 (de) | 1996-04-26 | 2004-05-19 | Genaera Corp. | Squalamin in kombination mit anderen antikrebs-mittelen zur behandlung von tumoren |
US7410959B1 (en) * | 2000-07-13 | 2008-08-12 | Genaera Corporation | Therapeutic uses for aminosterol compounds |
WO1997044044A1 (en) | 1996-05-17 | 1997-11-27 | Magainin Pharmaceuticals Inc. | Therapeutic uses for an aminosterol compound |
AU5194998A (en) | 1996-11-01 | 1998-05-29 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and uses therefor |
US6388108B1 (en) | 1998-08-12 | 2002-05-14 | Genaera Corporation | Aminosterol compounds and uses thereof |
US6288089B1 (en) * | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
WO2002032376A2 (en) | 2000-10-06 | 2002-04-25 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
US7144877B2 (en) * | 2000-10-06 | 2006-12-05 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
KR101166000B1 (ko) * | 2002-01-28 | 2012-07-16 | 교와 핫꼬 기린 가부시키가이샤 | 운동성 질환에 걸린 환자의 치료 방법 |
AU2003298514A1 (en) | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
US7981876B2 (en) | 2005-04-25 | 2011-07-19 | Ohr Pharmaceuticals, Inc. | Polymorphic and amorphous salt forms of squalamine dilactate |
TW200927755A (en) | 2007-09-06 | 2009-07-01 | Genaera Corp | A method for treating diabetes |
US8247435B2 (en) * | 2009-02-19 | 2012-08-21 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
WO2011056650A2 (en) | 2009-10-27 | 2011-05-12 | Michael Zasloff | Methods and compositions for treating and preventing viral infections |
WO2011066260A2 (en) | 2009-11-25 | 2011-06-03 | Michael Zasloff | Formulations comprising aminosterols |
KR102057812B1 (ko) | 2012-04-20 | 2019-12-19 | 오에이치알 파마서티컬, 인코포레이티드 | Ptp1b 연관 질병의 치료용 아미노스테로이드 |
CN102813659A (zh) * | 2012-08-21 | 2012-12-12 | 贵阳中医学院 | 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途 |
EP2934543B1 (en) | 2012-12-20 | 2018-10-31 | Mount Desert Island Biological Laboratory | Stimulation and enhancement of regeneration of tissues |
US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
-
2014
- 2014-07-11 US US14/329,627 patent/US10040817B2/en active Active
-
2015
- 2015-06-22 ES ES15811714T patent/ES2878077T3/es active Active
- 2015-06-22 PT PT158117143T patent/PT3157531T/pt unknown
- 2015-06-22 JP JP2016574402A patent/JP6692300B2/ja active Active
- 2015-06-22 WO PCT/US2015/036935 patent/WO2015200195A1/en active Application Filing
- 2015-06-22 CA CA2951720A patent/CA2951720C/en active Active
- 2015-06-22 BR BR112016029917A patent/BR112016029917A2/pt not_active Application Discontinuation
- 2015-06-22 EP EP15811714.3A patent/EP3157531B1/en active Active
- 2015-06-22 PL PL15811714T patent/PL3157531T3/pl unknown
- 2015-06-22 SI SI201531637T patent/SI3157531T1/sl unknown
- 2015-06-22 CN CN201580033333.7A patent/CN106535902B/zh active Active
- 2015-06-22 DK DK15811714.3T patent/DK3157531T3/da active
- 2015-06-22 MX MX2016017368A patent/MX2016017368A/es unknown
- 2015-06-22 RS RS20210819A patent/RS62064B1/sr unknown
- 2015-06-22 HU HUE15811714A patent/HUE054828T2/hu unknown
- 2015-06-22 CN CN202110489234.7A patent/CN113559108A/zh active Pending
- 2015-06-22 LT LTEP15811714.3T patent/LT3157531T/lt unknown
-
2016
- 2016-12-20 MX MX2021005489A patent/MX2021005489A/es unknown
-
2017
- 2017-05-24 US US15/604,489 patent/US10208079B2/en active Active
- 2017-05-24 US US15/604,527 patent/US10208080B2/en active Active
- 2017-05-24 US US15/604,452 patent/US10196420B2/en active Active
-
2018
- 2018-07-13 US US16/035,537 patent/US10633413B2/en active Active
- 2018-07-18 US US16/039,294 patent/US11440936B2/en active Active
- 2018-12-13 US US16/219,879 patent/US20190185513A1/en not_active Abandoned
- 2018-12-13 US US16/219,848 patent/US10975116B2/en active Active
- 2018-12-14 US US16/220,860 patent/US20190194244A1/en not_active Abandoned
-
2020
- 2020-01-21 JP JP2020007206A patent/JP7010979B2/ja active Active
-
2021
- 2021-06-24 HR HRP20211005TT patent/HRP20211005T1/hr unknown
- 2021-06-28 CY CY20211100573T patent/CY1124554T1/el unknown
-
2022
- 2022-04-01 US US17/711,891 patent/US20220220148A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3349783T3 (pl) | Kompozycje i sposoby do leczenia chorób | |
HUE054828T2 (hu) | Eljárások és készítmények a bél enteroendokrin rendszerének stimulálására a vele kapcsolatos betegségek és állapotok kezelésére | |
HK1246179A1 (zh) | 治療視網膜疾病的方法 | |
SG10201913564WA (en) | Compositions and methods for treatment of neurological disorders | |
IL246791A0 (en) | Compositions and methods for treating eye diseases | |
IL285003A (en) | Treatment of episode disorders | |
HUE055913T2 (hu) | Módszerek és készítmények a glioblastoma diagnosztizálására és kezelésére | |
IL253118A0 (en) | Methods for treating inflammatory diseases | |
HK1252037A1 (zh) | 治療炎性疾病的方法 | |
GB201404403D0 (en) | Compositions and methods relating to the treatment of diseases | |
HK1245127A1 (zh) | 治療腦疾病的方法和組合物 | |
HK1258994A1 (zh) | 用於疾病治療的方法 | |
HK1247818A1 (zh) | 治療疾病的方法 | |
EP3164132A4 (en) | Methods and compositions for treating diseases and conditions | |
IL259710A (en) | Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases | |
HK1244782A1 (zh) | 用於治療疾病和病癥的組合物和方法 | |
HK1246271A1 (zh) | 用於合成羥基-三甘油酯的方法及其用於預防和治療疾病的用途 | |
HK1243937A1 (zh) | 治療疾病的方法 | |
IL257689B (en) | Pharmaceutical preparations and methods for treating diseases related to lack of oxygen | |
GB201516303D0 (en) | Compositions and methods relating to the treatment of diseases | |
SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
GB201516437D0 (en) | Compositions and methods relating to the treatment of disease | |
AP2016009662A0 (en) | Combination of taurine and racemethionine for treatment of liver diseases |